Charles River Laboratories - 25 Year Stock Price History | CRL
Historical daily share price chart and data for Charles River Laboratories since 2000 adjusted for splits and dividends. The latest closing stock price for Charles River Laboratories as of May 16, 2025 is 140.97.
- The all-time high Charles River Laboratories stock closing price was 458.30 on September 24, 2021.
- The Charles River Laboratories 52-week high stock price is 254.15, which is 80.3% above the current share price.
- The Charles River Laboratories 52-week low stock price is 91.86, which is 34.8% below the current share price.
- The average Charles River Laboratories stock price for the last 52 weeks is 183.63.
| Charles River Laboratories Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2025 | 152.0989 | 182.6400 | 190.1400 | 99.7500 | 140.9700 | -23.63% |
| 2024 | 216.1551 | 234.2500 | 273.4300 | 178.5800 | 184.6000 | -21.91% |
| 2023 | 206.8410 | 218.4000 | 259.9200 | 164.5200 | 236.4000 | 8.49% |
| 2022 | 246.3805 | 362.1100 | 362.1100 | 182.4400 | 217.9000 | -42.17% |
| 2021 | 354.9112 | 249.6700 | 458.3000 | 249.6700 | 376.7800 | 50.80% |
| 2020 | 189.2381 | 153.8900 | 252.6200 | 98.9000 | 249.8600 | 63.56% |
| 2019 | 134.9265 | 111.0900 | 152.7600 | 104.8200 | 152.7600 | 34.97% |
| 2018 | 116.1663 | 110.6500 | 137.2300 | 98.1900 | 113.1800 | 3.41% |
| 2017 | 97.1831 | 76.5300 | 118.0900 | 76.5300 | 109.4500 | 43.65% |
| 2016 | 79.1136 | 78.2500 | 88.4400 | 67.1000 | 76.1900 | -5.22% |
| 2015 | 72.9128 | 63.8800 | 84.2000 | 61.5900 | 80.3900 | 26.32% |
| 2014 | 58.2804 | 52.8800 | 65.5900 | 50.7400 | 63.6400 | 19.98% |
| 2013 | 45.2635 | 38.0400 | 53.3600 | 38.0400 | 53.0400 | 41.55% |
| 2012 | 35.7702 | 27.7500 | 41.2400 | 27.3900 | 37.4700 | 37.10% |
| 2011 | 35.2187 | 35.8400 | 42.4700 | 25.9500 | 27.3300 | -23.10% |
| 2010 | 34.3705 | 33.5700 | 41.5600 | 28.2500 | 35.5400 | 5.49% |
| 2009 | 31.0983 | 26.8900 | 40.0900 | 23.1500 | 33.6900 | 28.59% |
| 2008 | 54.5137 | 65.1800 | 68.8200 | 20.7800 | 26.2000 | -60.18% |
| 2007 | 52.4677 | 43.2400 | 67.3500 | 43.2400 | 65.8000 | 52.14% |
| 2006 | 42.8401 | 42.6600 | 50.5600 | 33.9200 | 43.2500 | 2.08% |
| 2005 | 46.7138 | 45.3500 | 52.7100 | 41.7600 | 42.3700 | -7.91% |
| 2004 | 44.1685 | 34.0400 | 48.8700 | 33.7700 | 46.0100 | 34.02% |
| 2003 | 31.1122 | 38.5500 | 38.5500 | 24.7500 | 34.3300 | -10.78% |
| 2002 | 34.7652 | 32.4900 | 40.9800 | 27.8000 | 38.4800 | 14.93% |
| 2001 | 29.3127 | 26.1250 | 37.4000 | 18.0000 | 33.4800 | 22.30% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $6.822B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $136.657B | 25.63 |
| Elevance Health (ELV) | United States | $88.114B | 11.37 |
| CVS Health (CVS) | United States | $76.496B | 9.51 |
| Cencora (COR) | United States | $55.428B | 19.28 |
| DiDi Global (DIDIY) | China | $22.215B | 33.71 |
| Natera (NTRA) | United States | $20.400B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.620B | 13.36 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.158B | 0.00 |
| CochLear (CHEOY) | Australia | $11.298B | 0.00 |
| Doximity (DOCS) | United States | $10.912B | 50.83 |
| Revvity (RVTY) | United States | $10.655B | 18.34 |
| ICON (ICLR) | Ireland | $10.552B | 9.81 |
| Viatris (VTRS) | United States | $10.317B | 3.54 |
| Avantor (AVTR) | United States | $8.750B | 12.71 |
| Medpace Holdings (MEDP) | United States | $8.519B | 22.63 |
| HealthEquity (HQY) | United States | $8.446B | 41.55 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $4.185B | 38.74 |
| Bausch + Lomb (BLCO) | Canada | $4.171B | 24.58 |
| Sotera Health (SHC) | United States | $3.616B | 20.55 |
| Surgery Partners (SGRY) | United States | $3.029B | 39.39 |
| Alignment Healthcare (ALHC) | United States | $2.948B | 0.00 |
| Concentras Parent (CON) | United States | $2.925B | 16.90 |
| Organon (OGN) | United States | $2.280B | 2.42 |
| Ardent Health Partners (ARDT) | United States | $2.179B | 9.29 |
| Progyny (PGNY) | United States | $1.882B | 41.42 |
| Premier (PINC) | United States | $1.877B | 14.24 |
| GeneDx Holdings (WGS) | United States | $1.815B | 69.90 |
| PACS (PACS) | United States | $1.625B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.432B | 28.64 |
| Pediatrix Medical (MD) | United States | $1.278B | 9.73 |
| Teladoc Health (TDOC) | United States | $1.272B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.059B | 0.00 | |
| Agilon Health (AGL) | United States | $1.056B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| Nutex Health (NUTX) | United States | $0.967B | 14.61 |
| CareDx (CDNA) | United States | $0.896B | 14.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.857B | 8.02 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.681B | 4.59 |
| InnovAge Holding (INNV) | United States | $0.570B | 0.00 |
| Enhabit (EHAB) | United States | $0.545B | 44.83 |
| Auna S.A (AUNA) | Luxembourg | $0.514B | 13.63 |
| Sonida Senior Living (SNDA) | United States | $0.493B | 0.00 |
| LifeMD (LFMD) | United States | $0.439B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.367B | 0.00 |
| SBC Medicals (SBC) | United States | $0.361B | 0.00 |
| Oncology Institute (TOI) | United States | $0.230B | 0.00 |
| Beauty Health (SKIN) | United States | $0.217B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.204B | 0.00 |
| DocGo (DCGO) | United States | $0.143B | 23.33 |
| Sera Prognostics (SERA) | United States | $0.090B | 0.00 |
| KindlyMD (KDLY) | United States | $0.083B | 0.00 |
| So-Young (SY) | China | $0.083B | 0.00 |
| OncoCyte (OCX) | United States | $0.080B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.071B | 0.00 |
| NeueHealth (NEUE) | United States | $0.062B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.049B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.033B | 0.00 |
| Biodesix (BDSX) | United States | $0.032B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |